The efficiency of first-generation EGFR-TKIs, such as gefitinib, could reach 70–80% in NSCLC patients harboring EGFR mutations (exon 19 deletion and L858R)4, 29. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.